Get the Stockscreener App
48.18
0.80%
-0.39
Pre-market:
48.95
0.77
+1.60%
Nektar Therapeutics stock is traded at $48.18, with a volume of 1.65M.
It is down -0.80% in the last 24 hours and up +108.93% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$48.57
Open:
$48.5
24h Volume:
1.65M
Relative Volume:
0.81
Market Cap:
$916.31M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-33.00
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
+68.76%
1M Performance:
+108.93%
6M Performance:
+5,776%
1Y Performance:
+3,785%
1-Day Range:
$45.74
$49.01
1-Week Range:
$31.85
$49.01
52-Week Range:
$0.432
$49.01
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
48.18 | 843.09M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.55 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.31 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.83 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
762.89 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.93 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Invesco Ltd. Has $424,000 Holdings in Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics launches proposed public offering - MSN
Nektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin Sells 5,166 Shares - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin Sells 6,666 Shares - MarketBeat
Ieq Capital LLC Acquires 535,244 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Trading 7.3% HigherTime to Buy? - MarketBeat
Nuveen LLC Buys New Position in Nektar Therapeutics $NKTR - MarketBeat
Nektar jumps after Sanofi data misses expectations - MSN
Nektar Therapeutics (NASDAQ:NKTR) Stock Rockets 92% As Investors Are Less Pessimistic Than Expected - 富途牛牛
Why Nektar Therapeutics Rippled Higher This Week - MSN
Nektar says Rezolve-AD phase 2b results for rezpegaldesleukin selected for oral presentation at EADV 2025 - MarketScreener
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 - PR Newswire
Nektar Therapeutics chief R&D officer sells $57,692 in stock By Investing.com - Investing.com Nigeria
Nektar Therapeutics chief R&D officer sells $57,692 in stock - Investing.com India
Nektar Therapeutics CEO sells $430k in stock - Investing.com
Nektar Therapeutics to Webcast Participation in H.C. Wainwright and Stifel Healthcare Conferences in September 2025 - geneonline.com
Will Nektar Therapeutics outperform the market in YEARJuly 2025 Volume & Stock Market Timing Techniques - beatles.ru
Sanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher - MSN
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know - sharewise.com
Fibonacci Retracement Aligns with Support in Nektar TherapeuticsWeekly Trade Report & Precise Entry and Exit Recommendations - beatles.ru
Restoring Immune Balance: The Next Wave Of T Cell-Targeted Therapeutics - insights.citeline.com
Almitas Capital LLC Purchases 3,690,647 Shares of Nektar Therapeutics $NKTR - MarketBeat
Is Nektar Therapeutics still a buy after recent gains2025 Valuation Update & Free Risk Controlled Daily Trade Plans - beatles.ru
Charles Schwab Investment Management Inc. Has $975,000 Stake in Nektar Therapeutics $NKTR - MarketBeat
Can Nektar Therapeutics recover in the next quarter2025 Geopolitical Influence & Community Verified Trade Signals - Newser
What’s the beta of Nektar Therapeutics stockJuly 2025 Summary & Weekly Top Gainers Alerts - خودرو بانک
What is the dividend yield of Nektar TherapeuticsWatch List & Pattern Based Trade Signal System - خودرو بانک
Measuring Nektar Therapeutics’s beta against major indicesJuly 2025 Decliners & Expert Approved Momentum Trade Ideas - Newser
Top chart patterns to watch in Nektar TherapeuticsWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
Real time alert setup for Nektar Therapeutics performanceJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
What is Nektar Therapeutics’s TAM (Total Addressable Market)July 2025 Short Interest & Free Real-Time Market Sentiment Alerts - خودرو بانک
Nektar Therapeutics stock trend forecast2025 Momentum Check & Free Expert Verified Stock Movement Alerts - Newser
Nektar Therapeutics (NKTR) Surges on Rival's Disappointing Resul - GuruFocus
Combining machine learning predictions for Nektar TherapeuticsMarket Sentiment Report & Weekly Setup with High ROI Potential - Newser
Here's Why Shares in PTC Therapeutics Soared This Week - AOL.com
What does recent volatility data suggest for Nektar TherapeuticsJuly 2025 Summary & Real-Time Volume Triggers - Newser
Nektar Therapeutics stock jumps after Sanofi’s amlitelimab data disappoints By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) Surges 26.02% as Sanofi's Underwhelming AD Trial Highlights Competitive Edge - AInvest
Candlestick signals on Nektar Therapeutics stock todayPrice Action & Precise Entry and Exit Recommendations - Newser
News impact scoring models applied to Nektar TherapeuticsJuly 2025 Summary & Daily Stock Trend Reports - Newser
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics (NKTR) - GuruFocus
Long term hold vs stop loss in Nektar Therapeutics2025 Trading Volume Trends & Real-Time Volume Surge Alerts - Newser
Can Nektar Therapeutics expand into new marketsEarnings Risk Summary & Reliable Volume Spike Alerts - خودرو بانک
Analysts postive on Nektar opportunity after Sanofi data - Investing.com
What's Going On With Nektar Therapeutics Stock On Thursday?Nektar Therapeutics (NASDAQ:NKTR) - Benzinga
Nektar Therapeutics Surges 19.5%: What's Fueling the Sharp Intraday Move? - AInvest
Nektar Therapeutics Soars 23.4% on FDA Fast Track Designation and Analyst Upgrades—Can This Momentum Sustain? - AInvest
Nektar Therapeutics to Participate in Two Investor Conferences in September - Eastern Progress
Nektar Therapeutics Shares Rise Amid Sanofi's Disappointing Eczema Drug Results - AInvest
Nektar Therapeutics Shares Jump as Sanofi's Eczema Drug Results Miss Expectations in Study - MarketScreener
Nektar Therapeutics Shares Soar After Sanofi’s Amlitelimab Falls Short - MSN
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nektar Therapeutics Stock (NKTR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan | Chief R&D Officer |
Sep 04 '25 |
Sale |
33.52 |
1,721 |
57,693 |
17,462 |
| ROBIN HOWARD W | President & CEO |
Sep 05 '25 |
Sale |
38.53 |
6,666 |
256,851 |
56,008 |
| ROBIN HOWARD W | President & CEO |
Sep 04 '25 |
Sale |
33.70 |
5,166 |
174,108 |
62,674 |
0.88%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):